New schizophrenia drug trial seeks to calm acute psychotic episodes
NCT ID NCT07467993
Summary
This study is testing whether an experimental medication called GXV813 can safely reduce symptoms in adults hospitalized for an acute schizophrenia episode. Researchers will compare GXV813 against a placebo in 142 participants over 6 weeks, measuring changes in symptoms like hallucinations, delusions, and emotional withdrawal. The goal is to see if this new treatment can help control symptoms during a severe flare-up of the condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Arch Clinical Trials LLC
RECRUITINGSt Louis, Missouri, 63141, United States
Contact
-
Uptown Research Institute LLC
RECRUITINGChicago, Illinois, 60640, United States
Contact
Conditions
Explore the condition pages connected to this study.